Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Placebo-controlled, Double-blind, Interventional, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-PAOD for the Treatment of Peripheral Arterial Occlusive Disease (PAOD)

NCT03339973 is registered in ClinicalTrials.gov with RHEACELL GmbH & Co. KG as lead sponsor.

NCT NCT03339973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03339973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Placebo-controlled, Double-blind, Interventional, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-PAOD for the Treatment of Peripheral Arterial Occlusive Disease (PAOD)
Lead sponsor
RHEACELL GmbH & Co. KG
Phase
Phase 1/2
Overall status
Terminated
Start date
March 5, 2018
Completion date
May 15, 2020
Enrollment
24 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral arterial occlusive disease